louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05711745: Effects of Myofascial Induction Therapy on Pressure Pain and Ankle Range of Motion.
Official title: Effects of Myofascial Induction Therapy on Ankle Pressure Pain and Ankle Range of Motion in Latent Trigger Points of the Gastrocnemius Muscle. A Clinical Trial.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Fascia
Trigger Point Pain, Myofascial
Range of Motion
Pain
Lead sponsor: Mayuben Private Clinic
Sponsor class: OTHER
First posted: 2023-02-03
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: A pre-post study
Primary purpose: TREATMENT

Brief summary: In this study, it will be assessed if there are changes in ankle dorsiflexion and pressure pain after performing the myofascial induction technique in the calf.


Eligibility criteria: Inclusion Criteria:

* Subjects with no pain and with 18 to 30 years old.

Exclusion Criteria:

* (1) Diagnosis of lower limb injury, including any tendinopathy, bursitis, ligamentous involvement or fasciitis ,
* (2) history of lower limb surgery ,
* (3) participants were required not to have undergone ankle stretching or any other treatment,
* (4) diabetes due to possible alteration of arterial distal circulation,
* (5) deformities of the toes, such as hammer toes and hallux valgus. All subjects signed an informed consent form before participating in the study

Primary outcomes:
measure: Pressure pain threshold
timeFrame: Immediately before intervention.
measure: Range of motion with knee extended
timeFrame: Immediately before the intervention.
measure: Range of motion with knee flexed
timeFrame: Immediately before the intervention.
measure: Pressure pain threshold
timeFrame: Immediately after the intervention.
measure: Range of motion with knee extended
timeFrame: Immediately after the intervention.
measure: Range of motion with knee flexed
timeFrame: Immediately after the intervention.
Secondary outcomes:
Other outcomes:
Locations:
city: Madrid
country: Spain
facility: Eva María Martinez Jiménez
Study officials:
References:
Clinical trial NCT05662345: ACT-MBC: A Study of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer (MBC)
Official title: ACT-MBC: A Prospective Observational Impact Study of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Metastatic Breast Cancer
Lead sponsor: Menarini Silicon Biosystems, INC
Sponsor class: INDUSTRY
Collaborators: name: Medex15
First posted: 2022-12-22
Enrollment: 65
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Advanced/metastatic breast cancer of following subtypes/lines of systemic therapy in metastatic setting:

* Estrogen Receptor (ER)+/Human Epidermal growth factor Receptor 2 (HER2) - patients prior to starting 2nd line or later therapy
* Triple Negative (TN) patients prior to starting any line of systemic therapy

Brief summary: ACT-MBC prospectively assesses the impact of CTCs on treatment decisions, response assessment and prognosis in MBC patients.


Eligibility criteria: Inclusion Criteria:

1. Invasive breast cancer with radiographic and/or clinical evidence of advanced metastatic or unresectable disease
2. ER+/HER2- patients prior to starting 2nd line therapy or beyond OR ER/Progesterone Receptor (PR)/HER2-negative (Triple Negative) patients prior to starting any line of therapy
3. Measurable and/or non-measurable disease is allowed
4. Male or female breast cancer is allowed
5. Age \> 18 years
6. Willingness to provide mandatory blood specimens
7. Willing to return to enrolling institution for follow up imaging at least once

Exclusion Criteria:

1. Life expectancy of ≤ 6 months
2. Inability to provide blood samples based on the judgment of the treating provider

Primary outcomes:
measure: To prospectively evaluate the impact of CellSearch CTCs on treatment decisions and response assessment in MBC patients
timeFrame: 3 to 4 months
Secondary outcomes:
measure: Assess barriers and receptiveness of providers in using CTCs in clinical practice
timeFrame: 18 months
measure: Evaluate if CTC results correlate with response assessment and disease progression defined by standard of care imaging
timeFrame: 18 months
Other outcomes:
Locations:
city: Albert Lea
country: United States
facility: Mayo Clinic Health System Albert Lea
state: Minnesota
city: Mankato
country: United States
facility: Mayo Clinic Health System Mankato
state: Minnesota
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
city: Eau Claire
country: United States
facility: MCHS Eau Claire
state: Wisconsin
Study officials:
References:
Clinical trial NCT02868645: Interest of Serum Periostin Dosage in Patients With Bone Fibrous Dysplasia
Official title: Interest of Serum Periostin Dosage in Patients With Bone Fibrous Dysplasia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Bone Fibrous Dysplasia
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2016-08-16
Enrollment: 65
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Fibrous dysplasia is a rare bone disease which can cause pain and fractures. It has been shown that periostin is over expressed in fibrous component in patients bones ; but periostin has never been measured out in serum of patients, although it is easy to assess. This study aims to show whether serum periostin is elevated in serum of patients with fibrous dysplasia, and if it is more elevated in patients with severe forms of the disease.


Eligibility criteria: Inclusion Criteria:

* patients with fibrous dysplasia of the bone
* access to social security
* informed consent

Exclusion Criteria:

* no informed consent
* pregnancy
* patients with a history of conditions known to increase periostin serum (stade IV cancer, severe asthma, pulmonary fibrosis...)

Primary outcomes:
measure: Periostin rate in serum
timeFrame: At inclusion
Secondary outcomes:
measure: Periostin rate in serum according to the number of fibrotic bones
timeFrame: At inclusion
measure: Periostin rate in serum in patients with severe phenotype of the disease
timeFrame: At inclusion
measure: Periostin rate in serum in patients with Mac Cune Albright syndrome
timeFrame: At inclusion
Other outcomes:
Locations:
city: Lyon cedex 03
country: France
facility: Service de rhumatologie Pavillon F - Hôpital Edouard Herriot
Study officials:
References:
Clinical trial NCT05250245: Tolterodine Relieves Overactive Bladder Symptoms in Women With Moderate-to-severe Obstructive Sleep Apnea Syndrome
Official title: Effect of Combined Use of Tolterodine and Continuous Positive Airway Pressure vs Continuous Positive Airway Pressure Only Treatment on Overactive Bladder Symptoms in Women With Moderate-to-severe Obstructive Sleep Apnea Syndrome: A Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Overactive Bladder
Obstructive Sleep Apnea
Overactive Bladder Syndrome
Lead sponsor: Yuzuncu Yıl University
Sponsor class: OTHER
First posted: 2022-02-22
Enrollment: 60
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In this study, we aim to determine whether combined tolterodine and CPAP therapy is a more effective treatment for patients with OSAS than CPAP treatment only.


Eligibility criteria: Inclusion Criteria:

* Women older than 18 who underwent polysomnography test with suspicion of OSAS between 01.06.2020-01.01.2022 were enrolled in the study
* Patients with AHI ≥15 (moderate or severe) and OAB-V8≥8 were considered eligible for the study and randomized in two groups to receive either CPAP treatment only or CPAP treatment with tolterodine tartrate

Exclusion Criteria:

* Patients diagnosed with neurological diseases, diabetes mellitus, congestive heart failure, infection, hematuria, urolithiasis, urinary tumors, and urinary retention were excluded from the study. Also, a history of lower urinary tract surgery and medication due to lower urinary tract symptoms were the exclusion criteria.

Primary outcomes:
measure: OAB-V8 questionnarie score improvement
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Van
country: Turkey
facility: Yuzuncu Yıl University
Study officials:
References:
Clinical trial NCT05590845: Evaluating Patient Knowledge About Perioperative Neurocognitive Disorders (KNOW-PND Study)
Official title: Evaluating Patient Knowledge About Perioperative Neurocognitive Disorders (KNOW-PND Study)
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Anesthesia Complication
Lead sponsor: Université Libre de Bruxelles
Sponsor class: OTHER
First posted: 2022-10-21
Enrollment: 100
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients scheduled for elective total hip replacement surgery.

Brief summary: Neurocognitive disorders remain one of the major perioperative complications. They are associated with delayed recovery, prolonged length of hospital stay and impacts on patients' quality of life. The incidence of PND ranges from 15-50%.

While several causes have been investigated, PND seems to be due to the non-resolution of an inflammatory cascade, making some patients more at risk than others. As such, major risk factors include old age and lower education levels.

As the global proportion of people aged 60 and above between 2015 and 2050 will increase from 12% to 22% and worldwide surgeries increases to \>300 million procedures per annum the incidence of perioperative neurocognitive disorders with high morbidity and mortality will go up.

In 2015, the American Society of Anesthesiologists (ASA) launched the 'Perioperative Brain Health Initiative' to increase awareness about perioperative neurocognitive disorders. (PND) While physicians seems to be more and more aware about this condition, data regarding patient awareness are not available.

An observational, single-centre, cross-sectional survey study (with initially a feasibility study) will be conducted in patients, 65 years and above undergoing elective total hip replacement surgery at AZ Sint-Jan (Brugge, Belgium) to assess patients' basic knowledge regarding PND.


Eligibility criteria: Inclusion Criteria:

* age 65 and above
* ASA score 1 to 3
* scheduled for elective hip surgery.

Exclusion Criteria:

* insufficient knowledge of Dutch
* known neuropsychiatric conditions

Primary outcomes:
measure: PND knowledge
timeFrame: 1 week pre-operatively
Secondary outcomes:
measure: Baseline cognition
timeFrame: 1 week pre-operatively
measure: PND
timeFrame: 6 weeks post-operatively
Other outcomes:
Locations:
city: Brugge
country: Belgium
facility: AZ Sint-Jan Brugge Oostende AV
Study officials:
affiliation: AZ Sint-Lucas Brugge
name: Sarah Saxena, MD;PHD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02875145: Impact of Cataract Surgery on Keratoplasty Graft Survival
Official title: Impact of Cataract Surgery on Keratoplasty Graft Survival
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cataract
Fuchs' Endothelial Dystrophy
Keratoconus
Keywords: Corneal Transplantation
Graft Survival
Lead sponsor: Centre Hospitalier Universitaire de Besancon
Sponsor class: OTHER
First posted: 2016-08-23
Enrollment: 453
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients who underwent a keratoplasty between january 1983 and december 2012 at the University Hospital of Besançon.

Brief summary: The follow up time after keratoplasty now routinely exceeds multiple decades. It is common for keratoplasty patients to also undergo cataract surgery at a later date in their lives.

Keratoplasties and cataract surgery both result in local inflammation. This may influence the density of endothelial cells, and on average there is a loss of 10% in endothelial cells within 3 months of the cataract surgery. Yet, a sufficient density of endothelial cells is required to maintain graft transparency. It may be therefore difficult to strike a balance between loss of visual acuity due to the cataract of to the loss of graft transparency over the long term.

The investigators aim to compare graft survival in patients with clear crystalline lens with and without cataract surgery.


Eligibility criteria: Inclusion Criteria:

* All patients undergoing keratoplasty
* Between january 1983 and december 2012
* Age 40 and older at the time of surgery

Exclusion Criteria:

* Cataract surgery prior to the keratoplasty
* Systemic inflammatory disease
* Previous history of uveitis

Primary outcomes:
measure: Corneal transplant graft survival
timeFrame: 10 years
Secondary outcomes:
measure: Corneal endothelial cell density
timeFrame: 10 years
Other outcomes:
Locations:
city: Besançon
country: France
facility: Ophthalmology Department, CHU Besançon
Study officials:
affiliation: Opthalmology Department, CHU Besançon
name: Bernard Delbosc, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01208545: Serial Electrophysiologic Monitoring During Administration of Nerve-Toxic Chemotherapeutic Drugs
Official title: Serial Electrophysiologic Monitoring During Administration of Nerve-Toxic Chemotherapeutic Drugs
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Chemotherapy
Nerve Degeneration
Nerve Conduction
Keywords: taxol
vincristine
oxaliplatin
chemotherapy
nerve degeneration
nerve conduction
cancer
nerve conduction studies
Lead sponsor: NeuroMetrix, Inc.
Sponsor class: INDUSTRY
First posted: 2010-09-24
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients presenting to an oncology clinic for treatment of breast cancer, colon cancer, or non-Hodgkins lymphoma, or treatment of advanced gastroesophageal cancer

Brief summary: The study hypothesis is that changes in serially obtained nerve conduction study data obtained every 3-4 weeks in cancer patients receiving chemotherapy can be used to predict the development of a clinically significant / disabling drug induced neuropathy six and twelve months following the start of treatment. Patients with breast cancer, colon cancer, gastroesophageal cancer, and non-Hodgkins lymphoma will be enrolled. Six lower extremity nerves--three in each leg--will be electrically stimulated and their responses recorded at three to four week intervals coinciding with patient's scheduled chemotherapy.


Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of untreated breast cancer, treated (advance stage) or untreated colon cancer, untreated non-Hodgkins lymphoma, or advanced gastroesophageal cancer scheduled to begin chemotherapy with either Taxol, oxaliplatin, or vincristine

Exclusion Criteria:

* Individuals with an implanted electronic medical devices (cardiac pacemaker or defibrillator, vagus nerve stimulator, deep brain stimulator, intrathecal pump, others)
* Individuals whose chemotherapy regimen will include nerve toxic drugs other than Taxol, oxaliplatin, or vincristine, or includes more than one of these three drugs in combination
* Individuals whose screening nerve conduction studies show peroneal motor amplitude \< 1 mV bilaterally or sural sensory amplitude \< 3 uV bilaterally or no result obtainable

Primary outcomes:
measure: Time in weeks to fifty percent decrease in sural nerve action potential amplitude
timeFrame: one year
Secondary outcomes:
Other outcomes:
Locations:
city: Santa Clara
country: United States
facility: Santa Clara Valley Health and Hospital System
state: California
Study officials:
affiliation: NeuroMetrix, Inc.
name: Eugene A Lesser, D.O.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02537847: Sitafloxacin and Ertapenem Treatment for Acute Pyelonephritis Caused by Escherichia Coli
Official title: A Randomized Controlled Trial of Sitafloxacin and Ertapenem Treatment for Acute Pyelonephritis Caused by Extended-Spectrum ß-lactamase-producing Escherichia Coli
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Infection Due to Escherichia Coli
Acute Pyelonephritis
Keywords: Sitafloxacin
Extended-Spectrum ß-lactamase-producing Escherichia coli
Treatment for Acute Pyelonephritis
Ertapenem
Lead sponsor: Mahidol University
Sponsor class: OTHER
First posted: 2015-09-02
Enrollment: 96
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of the investigators' study was to evaluate oral and non carbapenem antimicrobial agents which can be used in outpatient for the treatment of non-bacteremic acute pyelonephritis caused by Extended Spectrum Beta Lactamase Escherichia coli. This study was conducted to compare the clinical and bacteriological outcomes of patients with non-bacteremic acute pyelonephritis caused by Extended Spectrum Beta Lactamase Escherichia coli who were treated with intravenous (IV) carbapenems followed by oral sitafloxacin or IV ertapenem.

Detailed description: A prospective randomized controlled trial of patients with a presumptive diagnosis of acute pyelonephritis caused by Extended Spectrum Beta Lactamase-producing pathogen was performed. Carbapenems was initially given to all patients. After day 3, patients were randomized to receive either oral sitafloxacin (100 mg twice daily) or intravenous ertapenem. The regular course of treatment was completed within 10 days.

Eligibility criteria: Inclusion Criteria:

* Age \>18 years
* Acute pyelonephritis by definition
* Positive urine culture for Extended Spectrum Beta Lactamase Escherichia coli ≥105 colony forming unit/mL
* Voluntarily consented to be enrolled in the study

Exclusion Criteria:

* Severe sepsis or septic shock
* Mixed organism of urine culture
* Positive blood culture
* Has other source of infection
* Has mechanical abnormality of urinary tract
* Immunocompromised conditions
* Retained Foley's catheter
* Pregnancy or lactation
* Previous urinary tract infections within 4 weeks
* Contraindicated for fluoroquinolones and carbapenems

Primary outcomes:
measure: no symptoms of urinary tract infection
timeFrame: 30 days
Secondary outcomes:
measure: no evidence of Extended Spectrum Beta Lactamase Escherichia coli in urine culture
timeFrame: 30 days
Other outcomes:
Locations:
city: Bangkok
country: Thailand
facility: Faculty of Medicine Ramathibodi Hospital
Study officials:
affiliation: Ramathibodi Hospital Mahidol University
name: Sasisopin Kiertiburanakul
role: STUDY_DIRECTOR
References:
Clinical trial NCT05750147: The SMARTER Cardiomyopathy Study
Official title: Genetics, Imaging and Artificial Intelligence for Precision Care in Cardiomyopathy
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Cardiomyopathies
Hypertrophic Cardiomyopathy
Dilated Cardiomyopathy
Lead sponsor: Imperial College London
Sponsor class: OTHER
First posted: 2023-03-01
Enrollment: 1000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: People with a diagnosis of cardiomyopathy, or a family member of cardiomyopathy or a genetic predisposition to cardiomyopathy of any age and any sex.

Brief summary: Cardiomyopathies are diseases of the heart muscle. Known genetic factors may account for some cardiomyopathy cases but there is still much to understand about the genetic and environmental causes and how the disease progresses.

Finding new ways to diagnose and treat cardiomyopathies could improve the health and well-being of patients with these conditions.

This study will collect data from individuals with cardiomyopathy or related heart muscle disease, or with a possible genetic predisposition to cardiomyopathy, and follow them over time to observe the progress of their heart and health. This study will collect DNA, blood samples, and detailed clinical \& lifestyle information at the start of the study, and data collected during routine healthcare visits over time.

* learn what causes cardiomyopathy, and therefore how to treat it
* understand why cardiomyopathy progresses differently in different people, to improve the ability to recognise who will benefit from different treatments at different times

The investigators will collaborate with other centres internationally to collect a large of group of participants with similar cardiomyopathies, providing power to identify new pathways that cause disease and ways of predicting which participants are at risk of having more severe disease.


Eligibility criteria: Inclusion Criteria:

Adults with the capacity to consent Children with parental/guardian consent Male and Female

Meeting the following criteria:

1. Patients with a confirmed diagnosis of cardiomyopathy or related condition
2. Patients with a family member with cardiomyopathy, or a related condition
3. Patients with a genetic variant that may predispose to cardiomyopathy, or a related condition

Exclusion Criteria:

Patients without the capacity to provide informed consent

Primary outcomes:
measure: Incidence of genetic variants
timeFrame: 5 years
measure: The incidence of major adverse cardiovascular events over 5 years
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: London
country: United Kingdom
facility: Guys & St Thomas' NHS Foundation Trust
city: London
country: United Kingdom
facility: Kings College Hospital
Study officials:
affiliation: Imperial College London
name: James Ware
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06466447: Child and Adolescent OCD Outcomes From Exposure and Response Prevention Video Teletherapy Treatment
Official title: Effectiveness of Video Teletherapy in Treating Child and Adolescent Obsessive-Compulsive Disorder With Exposure and Response Prevention: a Retrospective Longitudinal Observational Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Obsessive-Compulsive Disorder
Keywords: exposure and response prevention
digital behavioral health
remote treatment
video therapy
children
adolescents
Lead sponsor: NOCD
Sponsor class: INDUSTRY
First posted: 2024-06-20
Enrollment: 2173
Sex: ALL
Minimum age (years): 4
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This is a naturalistic sample of children and adolescents obsessive-compulsive disorder (OCD) who sought treatment for OCD from NOCD, Inc., a digital behavioral health company.

Brief summary: This is a naturalistic, observational study of children and adolescents with obsessive-compulsive disorder who were treated with exposure and response prevention via video teletherapy.


Eligibility criteria: Inclusion Criteria:

* obsessive-compulsive disorder

Exclusion Criteria:

* none

Primary outcomes:
measure: Dimensional Obsessive-Compulsive Scale
timeFrame: change from pre-treatment to post-treatment (after 11 weeks)
Secondary outcomes:
measure: Depression Anxiety and Stress Scale (DASS-21)
timeFrame: pre-treatment, after 4 weeks, and post-treatment (after 11 weeks)
Other outcomes:
Locations:
city: Chicago
country: United States
facility: NOCD, Inc.
state: Illinois
Study officials:
References: